In a groundbreaking move with the potential to revolutionise the treatment of cardiovascular diseases, Roche has entered into a licensing agreement with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. The deal, that could be worth up to US$2.8 B, combines Alnylam's cutting-edge RNAi technology with Roche's commercialisation expertise, clinical development capabilities, and global distribution network. Alnylam and Roche aim to accelerate the clinical development and regulatory approval process for zilebesiran.